The study of reserved liver function after TACE in hepatic carcinoma by 13C-methacetin breath test
10.3760/cma.j.issn.1006-9801.2010.11.008
- VernacularTitle:13C-美沙西丁呼气试验检测肝癌肝动脉化疗栓塞术后肝储备功能的研究
- Author:
Hongxia LI
;
Junping WANG
;
Ying YANG
;
Jin ZHANG
;
Qiuling FENG
;
Guangli LIU
- Publication Type:Journal Article
- Keywords:
Liver neoplasms;
Transcatheter arterial chemoembolization;
Classifications using 13C-methacetin breath test;
Liver function test
- From:
Cancer Research and Clinic
2010;22(11):742-744
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the changes of hepatic function before and after transcatheter arterial chemoembolization (TACE) in primary liver cancer patients with different quantifications and classifications using 13C-methacetin breath test (13C-MBT), and to provide risk predicts for TACE. Methods 28 cases of primary liver cancer patients and 10 cases of metastatic liver cancer patients were selected.General examination items of liver function and 13C-MBT detection were performed on all cases. Primary liver cancer was divided into 4 groups according to the results of 13C-MBT (group 1 was normal or pathological liver damage; group 2 was grade A; Group 3 was grade B; group 4 was grade C). 13C-MBT detection was carried out in week 1 and 4 after TACE. Results The three parameters of 13C-MBT is 13CO2 maximum excretion rate before 40 min/27 (MVmax40), 13CO2 cumulative excretion of 40 min/12 (CUM40), and than of 120 min/28(CUM120). Compared with the parameters [(0.628±0.191)%, (0.628±0.289)%, (0.577±0.286)%] before TACE in hepatic metastasis, there were no statistic effect between week 1 [(0.600±0.187)%, (0.559±0.189)%, 0.587±0.181)%] and week 4 [(0.700±0.230)%, (0.734±0.229)%, (0.724±0.252)%] after TACE. Conclusion The lower classification of 13C-MBT, the more impairment to liver function after TACE. This could provide an important diagnostic basis for TACE.
